Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients
- 31 October 1999
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 35 (10), 1462-1465
- https://doi.org/10.1016/s0959-8049(99)00157-4
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?Nature Medicine, 1996
- Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune EscapeScience, 1996
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagementCellular Immunology, 1992
- The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosisCell, 1991
- p53 Mutations in Human CancersScience, 1991
- p53: A Frequent Target for Genetic Abnormalities in Lung CancerScience, 1989
- Monoclonal Antibody-Mediated Tumor Regression by Induction of ApoptosisScience, 1989
- A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.The Journal of Experimental Medicine, 1989
- Involvement of the bcl -2 Gene in Human Follicular LymphomaScience, 1985